Sadeghian G, Ziaei H, Nilforoushzadeh M A
Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Acta Dermatovenerol Alp Pannonica Adriat. 2011;20(4):187-90.
Psoriasis is a common chronic condition of the skin that is resistant to many therapies.
To test the efficacy of a topical formulation of zinc pyrithione in an emollient base compared with an emollient alone in the treatment of psoriasis.
This was a randomized double-blind clinical trial. Patients with localized psoriasis involving less than 10% of body skin areas were enrolled in the study. They were randomly allocated to one of two treatment groups. Group A was treated with emollient cream containing 0.25% zinc pyrithione and group B was treated with emollient cream alone twice daily for 3 months. Response to treatment was assessed using PASI scores.
Of 60 participants, 30 patients in group A and 30 patients in group B completed the study. The mean PASI scores before and after treatment were 3.4±1.8 and 0.9±1.3 in group A (p<0.01), and 4.3±2 and 3.9±1.3 in group B (p>0.05), and there was a significant difference between the two groups' mean PASI scores at the end of the study (p<0.01). The differences in the mean PASI scores before and after treatment were 2.4±2 and 0.4±0.1 in groups A and B, respectively (p<0.01).
A topical formulation of zinc pyrithione can be used to treat localized psoriasis.
银屑病是一种常见的慢性皮肤病，对多种治疗方法均有抗性。
测试在润肤基质中添加吡啶硫酮锌的局部用制剂与单纯润肤剂相比，在治疗银屑病方面的疗效。
这是一项随机双盲临床试验。纳入身体皮肤受累面积小于10%的局限性银屑病患者。他们被随机分配至两个治疗组之一。A组使用含0.25%吡啶硫酮锌的润肤霜治疗，B组仅使用润肤霜治疗，每日两次，为期3个月。使用银屑病面积和严重程度指数（PASI）评分评估治疗反应。
60名参与者中，A组30例患者和B组30例患者完成了研究。A组治疗前后的平均PASI评分分别为3.4±1.8和0.9±1.3（p<0.01），B组为4.3±2和3.9±1.3（p>0.05），研究结束时两组的平均PASI评分存在显著差异（p<0.01）。A组和B组治疗前后平均PASI评分的差异分别为2.4±2和0.4±0.1（p<0.01）。
吡啶硫酮锌局部用制剂可用于治疗局限性银屑病。
